Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, County Mayo, Ireland
ZORAC 0.05%, gel.
| Pharmaceutical Form |
|---|
|
Gel. Colourless to light yellow, translucent to homogeneous cloudy gel. |
Active substance: Tazarotene 0.05g.
Excipients with known effect:
Butylhydroxyanisole: 0.05g
Butylhydroxytoluene: 0.05g
For 100g of gel.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tazarotene |
Tazarotene, a member of the acetylenic class of retinoids, is a prodrug which is converted to its active free form, tazarotenic acid, by de-esterification in the skin area. Tazarotenic acid is the only known metabolite of tazarotene to have retinoid activity. |
| List of Excipients |
|---|
|
Benzyl alcohol |
10g, 15g, 30g, 50g, 60g and 100g in tube (aluminium, internally lacquered epoxyphenolic) with white polypropylene cap.
Not all pack sizes may be marketed.
Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, County Mayo, Ireland
PL 41443/0003
30th July 1997 / 3rd December 2006
| Drug | Countries | |
|---|---|---|
| ZORAC | Spain, New Zealand, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
